Categories
Politics

Democrats See Early Edge in 2022 Senate Map

Three other Republicans in the running outperformed Mr. Greitens: Rep. Vicky Hartzler, Attorney General Eric Schmitt, and Mark McCloskey, best known for waving his gun outside his St. Louis home when protesters marched last year. Some national Republican strategists fear that if Mr. Greitens survives a crowded primary, he could prove toxic even in a heavily Republican state.

Scott has promised to remain neutral in the party’s primary election, but Kentucky Senator Mitch McConnell, the Republican leader, has long preferred promoting candidates he believes can win in November.

“The only thing that matters to me is eligibility,” McConnell told Politico this year. With Mr. Scott on the sidelines, a McConnell-sponsored super-PAC, the Senate Leadership Fund, is expected to handle most of the interventions.

Mr. Trump, who often argues with Mr. McConnell, has been particularly involved in the races in Arizona and Georgia, largely because of his own narrow losses there. He has publicly urged former soccer player Herschel Walker to run in Georgia – Mr Walker has not signed up to a campaign – and attacked Arizona Republican Governor Doug Ducey, even after Mr Ducey said he was not running for the Senate is running. Some Republican agents continue to hope to pull Mr. Ducey into the race.

Mr. Trump gave early Senate approval to North Carolina MP Ted Budd, who raised $ 953,000, which is less than the $ 1.25 million withdrawn from former Governor Pat McCrory. Some Republicans see Mr. McCrory as the stronger potential candidate because of his track record in winning nationwide.

In Alaska, Kelly Tshibaka is running as a pro-Trump challenger for Senator Lisa Murkowski, who voted for Trump’s conviction after his second impeachment. Ms. Murkowski, who has not officially said whether she will run again, more than doubled Ms. Tshibaka in the most recent quarter, from $ 1.15 million to $ 544,000.

In Alabama, Trump gave MP Mo Brooks another early endorsement and recently attacked one of his rivals, Katie Britt, the former chief of staff for retired incumbent Richard Shelby. Ms. Britt entered the race in June, but she raised Mr. Brooks by $ 2.2 million to $ 824,000. A third candidate, Lynda Blanchard, is a former Trump-appointed ambassador who loaned $ 5 million to her campaign.

Categories
World News

Asia-Pacific shares edge increased; Australia central financial institution’s fee choice forward

SINGAPORE — Shares in major Asia-Pacific markets edged higher on Tuesday morning as investors look ahead to the Australian central bank’s interest rate decision.

The Nikkei 225 and Topix index in Japan both rose fractionally in morning trade. Over in South Korea, the Kospi gained 0.24%.

Meanwhile, stocks in Australia climbed as the S&P/ASX 200 advanced 0.22%.

MSCI’s broadest index of Asia-Pacific shares outside Japan traded 0.08% higher.

Looking ahead, the Reserve Bank of Australia is set to announce its interest rate decision at 12:30 p.m. HK/SIN on Tuesday.

Stock picks and investing trends from CNBC Pro:

US crude futures jump

U.S. crude futures jumped in the morning of Asia trading hours on Tuesday, rising 1.57% to $76.34 per barrel. International benchmark Brent crude futures were fractionally higher at $77.19 per barrel.

Shares of Asia-Pacific firms in the oil space rose in Tuesday morning trade, with Australia’s Beach Energy rising 1.57% while Santos gained 1.44%. Shares of Inpex in Japan also jumped 1.19%.

Oil prices surged to multiyear highs on Monday after talks between OPEC and its oil-producing allies, known as OPEC+, were postponed indefinitely following a failure by the group to reach on agreement on production policy for August and beyond.

Currencies

The U.S. dollar index, which tracks the greenback against a basket of its peers, was at 92.241 — off levels above 92.4 seen late last week.

The Japanese yen traded at 110.86 per dollar after touching levels around 110.8 against the greenback yesterday. The Australian dollar changed hands at $0.7541, above levels below $0.752 seen yesterday.

Here’s a look at what’s on tap:

  • Australia: Reserve Bank of Australia’s interest rate decision at 12:30 p.m. HK/SIN

— CNBC’s Pippa Stevens contributed to this report.

Categories
World News

High shareholder Data Edge on the preliminary public providing

A Zomato Delivery boy adjusts a grocery order in his delivery bike amid the Covid-19 (Coronavirus) pandemic on November 8, 2020 in New Delhi, India.

Nasir Kachroo | NurPhoto | Getty Images

Indian internet company Info Edge has no plans to sell its entire stake in Zomato if the grocery delivery startup goes public, a senior executive said.

Zomato filed for an initial public offering of up to Rs. 82.5 billion ($ 1.1 billion) in April, in which the company will issue new shares valued at up to Rs. 75 billion. The company plans to use the proceeds to fund organic and inorganic growth initiatives, which may include mergers or acquisitions.

Info Edge, the startup’s largest shareholder, will sell shares valued at up to 7.5 billion rupees ($ 101 million), the company said in an IPO in April.

“We continue to invest in Zomato, we will not sell our entire stake,” said Chintan Thakkar, CFO and Executive Director at Info Edge, told CNBC’s Street Signs Asia on Tuesday.

Zomato participants

Info Edge was the first institutional investor to support Zomato and, according to Thakkar, currently holds around 17% of the shares in the start-up. Other shareholders include rideshare giant Uber, Alibaba subsidiary Ant Group and Singapore state investor Temasek.

“What we announced is that we could hit up to $ 100 million,” he said, referring to the number of Zomato shares Info Edge could sell. “We still have the option of not paying even $ 100 million.”

“Most of our stake will likely stay in Zomato, so we will keep investing in it,” said Thakkar.

Thakkar didn’t want to reveal when Zomato’s IPO could take place.

He said anything Info Edge receives from the offering will be added to existing funds that are likely to be used in the company’s operations and can be used to buy or acquire a strategic minority stake in potential midsize companies.

Info Edge will primarily deal with technology startups or “anything that has a sizeable market and can disrupt the existing market,” he added.

India’s fragmented food delivery scene

Together with rival start-up Swiggy, Zomato dominates the US $ 4.2 billion grocery delivery market in India, which is highly competitive but also very fragmented.

In its prospectus, Zomato said it faces intense competition from chain restaurants that have their own online ordering platforms. Other competitors are cloud kitchens and restaurants that operate their own delivery fleets, as well as offline orders over the phone.

The company also said the pandemic had a significant impact on business last year as most restaurants were temporarily closed and many customers were unwilling to order outside food. Zomato said its restaurant service income was also severely impacted.

In February, Zomato said it raised $ 250 million from donors like Tiger Global Management and Fidelity. That was months after a $ 660 million financing round closed.

Categories
Health

‘On That Fringe of Concern’: One Lady’s Battle With Sickle Cell Ache

NASHVILLE — She struggled through the night as she had so many times before, restless from sickle cell pain that felt like knives stabbing her bones. When morning broke, she wept at the edge of her hotel-room bed, her stomach wrenched in a complicated knot of anger, trepidation and hope.

It was a gray January morning, and Lisa Craig was in Nashville, three hours from her home in Knoxville, Tenn., preparing to see a sickle cell specialist she hoped could do something so many physicians had been unable to do: bring her painful disease under control.

Ms. Craig, 48, had clashed with doctors over her treatment for years. Those tensions had only increased as the medical consensus around pain treatment shifted and regulations for opioid use became more stringent. Her anguish had grown so persistent and draining that she sometimes thought she’d be better off dead.

She was willing to try just about anything to stop the deterioration of her body and mind — and her hope on this day in January 2019 rested in a Nigerian-born physician at Vanderbilt University Medical Center who had long treated the disease, which mostly afflicts people of African descent.

That morning, she slipped on a cream-colored cardigan and a necklace with a heart-shaped pendant. She played some Whitney Houston before sliding behind the wheel of her black S.U.V. Her husband, in the passenger’s seat, punched their destination into his phone’s navigation system.

“Live as if everything is a miracle,” reads a framed quote on Ms. Craig’s beige living room wall, and that’s exactly what she was hoping for.

People with sickle cell, a rare, inherited blood disorder caused by a mutation in a single gene, typically endure episodes of debilitating pain as well as chronic pain. Roughly 100,000 Americans and millions of people globally, mostly in Africa, have the disease. Red blood cells that carry oxygen become stiff and curved like crescent moons, clogging blood vessels and starving the body of oxygen.

Promising developments in gene therapy have given people with the disease hope that a cure is on the way for an illness that often causes organ failure and premature death. But the first such therapy is more than a year from regulatory approval. It will almost certainly be extremely expensive, cannot reverse the disease’s damage to tissues and organs, and may come too late for people whose bodies are so battered by the disease that they might not survive the grueling treatment.

Most people with sickle cell are searching for something far more basic: a way to prevent or manage the disease’s devastating complications — strokes, depression and, above all, pain.

That search can be rocky, as I learned following Ms. Craig over two and a half years of struggle and heartache. I joined her on doctor’s visits, shared meals with her family, parsed her medical records, sat in on a therapy session and tagged along as she ran errands around Knoxville and relaxed at home. I saw moments of anger, sadness and agony, but also determination, joy and love.

Her efforts to find relief were complicated by a national opioid epidemic and the coronavirus pandemic, as well as the challenges of navigating a medical system that often mistreats Black people like her. At the same time, doctors were changing how they treated sickle cell as emerging research suggested that narcotics could actually worsen pain.

Ms. Craig felt doctors were prone to stereotyping her as an addict cadging narcotics and didn’t believe in the extremity of her suffering.

Racist myths persist in medical care, like the idea that Black people tolerate more pain than white people. Such stereotypes have led Black patients to receive poor care, extensive research suggests. That can be especially problematic for sickle cell patients like Ms. Craig, who describe rushing to the emergency room in agony and waiting hours to be seen, only to be sent home still in pain after doctors tell them that their lab results are fine and they should not be suffering.

Biopsies can detect cancer, X-rays a broken bone. But there is no definitive clinical test to determine when a sickle cell patient is suffering a pain crisis.

“This is the essence of the problem,” said Dr. Sophie Lanzkron, the director of the Sickle Cell Center for Adults at the Johns Hopkins Hospital. “There is no objective measure of crisis. The gold standard is the patient tells you, ‘I am having a crisis.’”

The intensity of the disease as well as the subjectivity of treatment mean that a visit to a new doctor can feel like the cruelest game of roulette. And the weight of that pressure bore down on Ms. Craig as she parked at Vanderbilt and hobbled into the elevator. Would the doctor help her?

“Chest hurts,” she told her husband.

“You’ll be all right,” he assured her.

The throbbing pounded the little girl’s body. It was in her arms and legs, and it often made her sob.

Lisa’s parents were baffled. Her mother gave her warm baths and body rubs, and took her to the doctor frequently. But the pain persisted.

Then one day in the late 1970s, when Lisa was about 5, her parents drove her from their home in Knoxville to the Mayo Clinic in Rochester, Minn. Doctors ran tests and discovered the cause: sickle cell disease.

At the time, widespread screening for the illness in newborns was still about a decade away. Lisa was the only person in her extended family ever to have it diagnosed.

“That was something that was unheard-of,” she said.

Her mother was often her protector, coddling her when the pain set in, while her father urged her to carry on.

Flare-ups of pain made her miss out on slumber parties, ice skating and plenty of school. But for all the restrictions, no one ever questioned whether her pain was real.

At the East Tennessee Children’s Hospital where she was treated, the rooms were decorated with ocean- or circus-themed wallpaper. Nurses gave her games and puppets and tried to make her smile.

“Pain medication was given because people believed I was in pain,” she wrote in her journal decades later.

The medicines gave her relief, but also set her body on a path complicating her treatment decades later: She needed opioid painkillers to live comfortably.

A crisis was brewing in society that complicated efforts to treat pain caused by sickle cell: the spread of addiction to opioids fueled in large part by reckless, even criminal marketing of the drugs by major pharmaceutical companies.

Research showed that people with sickle cell were no more likely to become addicted to opioids than other chronic pain sufferers, and that their use of narcotics had not skyrocketed as it had in the general population.

In March 2016, the Centers for Disease Control and Prevention released stringent guidelines on prescribing narcotic painkillers, though it carved out exceptions for sickle cell.

A few months later, Ms. Craig’s doctors began cutting back on the amount of intravenous narcotics she was given for pain crises. She argued that the reduced doses were not working. Her hematologist, Dr. Jashmin K. Patel, urged her to take hydroxyurea, a chemotherapy drug that is a standard treatment for the disease, saying it would reduce her pain, according to medical records. Ms. Craig had tried it, but had an unusually severe reaction, with mouth sores, hair loss and vomiting, so she stopped. She said she felt that the doctor wasn’t taking her complaints about the side effects seriously. (Most patients can take the drug successfully.)

“Why do you dear doctor still bully me to take it,” Ms. Craig wrote in her journal on Sept. 17, 2017.

She didn’t want a doctor who preached to her, she wrote, but one who listened, because as someone “who deals with how MY body works with this disease don’t you think my expertise outweighs yours.”

Over the past decade, even some of the best-informed sickle cell specialists have begun reconsidering their reliance on long-term opioid therapy. They have found little evidence to suggest that sickle cell patients who regularly take opioids see their quality of life improve. And their concern about long-term reliance on narcotics is especially high in patients like Ms. Craig, who are living well into middle age with a disease that used to kill its sufferers in childhood or early adulthood.

Dr. Lanzkron at Johns Hopkins said her patients would “end up on these ridiculous doses” and “still have the same level of pain.”

“It’s a terrible treatment,” she said.

So the specialists started trying to teach people with sickle cell how to lessen and tolerate pain with techniques including therapy, meditation and hypnosis.

Ms. Craig had tried everything — warm baths, elevating her feet, steady breathing. She hated feeling dependent on pills. Yet she dreaded the way a simple ache crescendoed to feel like a thousand bee stings or a hand smashed in a door.

In July 2018, her need for relief led to conflict during a visit with Dr. Patel. Alarm bells began ringing in Ms. Craig’s head when the doctor stepped into the room accompanied by a stenographer.

Dr. Patel said she was concerned that Ms. Craig was not taking hydroxyurea as she was supposed to, according to medical records reviewed by The New York Times. She told Ms. Craig that she was not going to increase her pain medication, noting in the file that Ms. Craig had called two weeks earlier for a refill.

Ms. Craig said in an interview that she had never asked for an increase in medication and that Dr. Patel was twisting her words and ignoring her concerns. Neither Dr. Patel nor the practice where she worked responded to requests for comment.

Voices were raised, feelings hurt. Eight days later — on July 18, 2018 — Ms. Craig got a letter from Dr. Patel saying she was no longer welcome at the practice, “because of your lack of cooperation in your medical treatment, non-compliance with treatment recommendations and frequent narcotic requests before agreed time-frame.”

After she was kicked out of Dr. Patel’s practice, Ms. Craig went to Dr. Wahid T. Hanna, a veteran oncologist at the University of Tennessee Medical Center, who had treated dozens of sickle cell patients.

By December 2018, familiar tensions arose. Dr. Hanna grew suspicious of her request for narcotics. She had gone through the 120 Oxycodone pills that he had prescribed a month earlier and wanted a refill.

On several visits, Dr. Hanna repeated a refrain as if he were saying it for the first time: He was puzzled that she had pain because she had a generally less severe version of sickle cell.

“So really, I don’t have any justification why should you have pain,” he told her on one of those visits.

“I’ve always had pain,” she replied, according to a recording Ms. Craig’s husband took of the meeting.

Months earlier, Tennessee had enacted some of the nation’s most stringent restrictions on doctors prescribing opioids during a deadly epidemic, though there were exceptions for sickle cell patients.

“My question is, with the way the state is regulating the narcotics and all that, we could be questioned,” Dr. Hanna said. “We could be red-flagged.”

If Ms. Craig had pain, Dr. Hanna said it might have been from arthritis or the heavy periods she complained of. Those could be managed without opioids, he said.

“We do this every time I come, and I’m not understanding,” Ms. Craig said.

“I’m saying this because we can be questioned,” Dr. Hanna said, and if the authorities asked him whether he saw a lot of pain in someone with her kind of sickle cell, “I’d say usually I don’t.”

“You can’t say 100 percent that it’s not possible,” Ms. Craig said.

“I want to take care of you, but I want to do it right,” he said.

In that moment, Dr. Hanna said in a later interview, “I did not know whether her pain requirements were genuine or not.”

Her red blood cell count was stable and her iron was low — metrics that, Dr. Hanna said, suggested that her sickle cell was not that severe. But experts who treat sickle cell say that iron and hemoglobin levels do not indicate how severe the disease is.

Still, Dr. Hanna reduced her narcotic dosage, encouraged her to use over-the-counter pain medicines and scheduled her for an iron infusion, which he told her would make her “feel like a different person.”

Days after another disappointing visit to Dr. Hanna in December 2018, Ms. Craig sat on a light green leather couch beneath a painting of an ocean in her therapist’s office, choking back tears.

“Putting up with somebody belittling me and making me feel less than is not worth it,” she told her therapist.

It was difficult enough to control her physical pain, but reining in the mental anguish proved equally troublesome.

A former preschool teacher who speaks with wide-eyed animation, Ms. Craig has not been able to work full time since 2005 because of her unpredictable pain. She finds purpose where she can, taking care of her family, picking up the occasional odd job, babysitting for relatives and friends.

She exercised as her doctors advised, took 15 minutes a day to “be selfish” as a friend suggested and wrote prayers on brown slips of paper that she sealed in a jar. She listened as her therapist explained that there was no shame in trying to get prescriptions to relieve pain.

But all around, the signals told Ms. Craig otherwise: the constant stream of news about the opioid crisis and, one evening shortly before her Vanderbilt visit, a heated discussion with an aunt at the family dining room table.

“You can’t just come on in there and just say: ‘Look, this is the drug I take. And I know this’ll work,’” said her aunt, Nanette Henry Scruggs, who used to work at a hospital.

“The hospitals tell people all the time to be your own advocate,” Ms. Craig said.

Times were changing, her aunt explained, because doctors had overmedicated pain patients and now risked losing their licenses.

“You don’t understand it because you have the disease,” Ms. Scruggs said.

“And you don’t understand it because you don’t,” Ms. Craig fired back, her voice straining with emotion. “And you’re not the one that they look at and go, ‘Oh, she’s just exaggerating her pain.’ When I want to saw my own freaking legs off, that’s a problem!”

Many sickle cell patients feel frustrated that doctors don’t believe patients know what works. Often, that’s narcotic doses much higher than the average person requires. Yet asking for specific medications can fuel distrust, compounded by many doctors’ lack of familiarity with sickle cell.

Only one in five family physicians said they were comfortable treating sickle cell, according to a 2015 survey. Even hematologists rarely specialize in it, with a greater focus on cancers of the blood, which are more prevalent.

Ms. Craig lamented that sickle cell patients did not seem to get the sympathy given to people with other devastating illnesses. Somebody needed to change that, she told her aunt, “and I’m going to be that somebody.”

“Sickle cell patients are not abusing, are not the major cause of people overdosing,” Ms. Craig told her.

“I’m not saying that,” her aunt said, later adding, “She’s thinking I’m against her.”

“I’m not saying you’re against me, but you’re definitely not standing shoulder to shoulder with me,” Ms. Craig said.

Ms. Craig was now worked up, and her husband, Jeremy, urged her to calm down. He has long been her champion, but Ms. Craig worried her disease was a drag on her family. Jeremy, 45, their daughter, Kaylyn, 19, and their son, Mason, 15, have endured her at her weakest and angriest. They accompany her on middle-of-the-night emergency room runs and wake up when she paces their single-story brick home in the middle of the night because of pain.

Still, they have always looked out for her. Her husband first learned that she had sickle cell when they were dating and she told him that she was having a pain crisis. He drove her to the emergency room at 2 a.m., kissed her on the forehead and told her he loved her. She was sold. And because he was white, there was a lower chance that he would carry the sickle cell mutation, meaning it was less likely that their children would have the disease — something she also found appealing.

For Mr. Craig, simply watching his wife suffer was not an option. He always looked for solutions and thought he’d come up with one as he scrolled through his cellphone one evening in their dim living room: marijuana.

“I think you should try it,” he said.

Ms. Craig waved him off, but he insisted that it would be safe to try in states where it was legal.

“What if it works?” he asked.

“What if it doesn’t,” she replied. “I’m done talking to you about that whole situation.”

“If we go to Washington State,” he insisted.

“I’m not going,” she said, cutting him off. “To me, that feels like an addict.”

Still, she was desperate for help as her relationship with Dr. Hanna deteriorated. A social worker suggested she consult specialists at Vanderbilt.

She made the appointment. Just a few days before the visit, she made her fourth trip to the emergency room in six weeks for a pain crisis. The doctor gave her intravenous Tylenol and four oxycodone tablets. After four hours, she was still in pain and left the hospital, as she had many times, without relief.

“I want to be extremely honest with u and let you know I am tired,” she wrote to me on Facebook at 1:16 a.m., after getting home from the emergency room. “I feel beaten down by these doctors as if I am an addict.”

She was hurtling, she said, toward “a dangerous level of depression.”

Ms. Craig fidgeted and sweat beaded around her lip, forehead and eyes. It was Jan. 18, 2019, and, at last, she sat in an exam room at Vanderbilt.

Dr. Adetola A. Kassim strolled in, chomping gum. He shook hands with her and her husband.

“So what brings you?” he asked.

For half an hour, Ms. Craig guided him through her arduous journey: hip replacement, seizures, blood clots. Pain crises usually came right before her period, she told him, and he said that researchers were exploring whether there was a link between sickle cell pain and menstruation.

Dr. Kassim, who heads Vanderbilt’s adult sickle cell program, is a native of Nigeria who has specialized in treating the disease for more than 20 years. As he listened to her medical history and symptoms, he contemplated the riddle of treating her.

“What you’ve had over the years is an interplay of your disease with other chronic health problems,” he told her. “I’m going to think about it carefully because you’re a little complicated.”

He told Ms. Craig that he needed to run tests to figure out the underlying causes of her chronic pain. Did she, for instance, have arthritis? Since hydroxyurea had so many side effects for her, he wanted to try another drug, Endari.

And he wanted to manage her pain with sparing narcotic use. He worried she was susceptible to hyperalgesia, a condition in which prolonged opioid use can alter patients’ nerve receptors and actually cause more pain.

In many ways, he was echoing Dr. Hanna. She needed to take fewer narcotics. Sickle cell probably was not the cause of some of her pain. But he never questioned whether she was hurting. He listened. He laid out a plan.

“You can’t just come in one day and be like a cowboy,” Dr. Kassim said in a later interview. “You’ve got to win their trust and begin to slowly educate them.”

After she left his office that day, Ms. Craig leaned her head on her husband’s shoulder. “I feel like we should have come here a long time ago,” she said.

Three months after her first visit with Dr. Kassim, pain radiated through her lower back, left hip, elbows and knees. She was out of hydrocodone, and her next refill was more than a week away.

“Continue alternating between Aleve and extra strength Tylenol,” Karina L. Wilkerson, a nurse practitioner in Dr. Kassim’s office, counseled her in an email, prescribing a muscle relaxer and telling her: “Rest, heat and hydrate.”

Days later, the pain was so unrelenting that Ms. Craig went to the emergency room and got a dose of intravenous narcotics.

She felt as if history was repeating itself. She was trying to wean herself from opioids, to rely mostly on over-the-counter meds, to use heat and ice, but it was not working.

“I feel like I’m a junkie,” she said in an interview, her voice cracking.

The pain returned a day after she left the hospital. With four days until her next visit to Dr. Kassim, she sent another message to ask whether there was anything more to be done, careful not to request hydrocodone. A nurse wrote that she could be prescribed more muscle relaxers, but “we cannot fill any narcotics for you before your appointment.”

Ms. Craig felt as if she was back where she started. Dr. Kassim was friendly, attentive and knowledgeable, yet she was still enduring pain.

“A part of me knew we’d be back in this position,” she said, “that it was too good to be true.”

One day last May, Ms. Craig had spent a lot of time on her feet at a family gathering after a relative’s death. As she settled in for the evening, a family friend dropped off two children she had agreed to babysit, and she braced for the inevitable result of a busy day: pain.

In the past, she would have taken a hydrocodone earlier in the day as a maintenance dose. But she had been seeing Dr. Kassim for more than a year, and although pain continued to gnaw at her, she was starting to buy into his advice. She had paid close attention to Facebook groups and news from medical journals with the latest developments on sickle cell. In her 48th year battling the disease, her perspective was changing.

She had come to realize that no matter how much hydrocodone she took or how well versed her doctor was in the disease, her pain did not disappear — and that the medical consensus had shifted against relying mainly on narcotics.

“It’s like a defeated acceptance,” she said.

In the wee hours of the morning after the family gathering, she began to hurt. Her hips throbbed. She tried to sleep on her left side, then her right. She lay on her back and elevated her feet. Nothing worked.

Still, she held off on the narcotics. Most people with sickle cell remember a crisis when their pain was “at a zillion and you were sitting in that emergency room, waiting for them to call you, and all you wanted to do was pass out,” she said. “We live on that edge of fear.”

She held off until about 11 a.m., when she took a hydrocodone. It provided enough relief to keep her out of the hospital — just the kind of progress Dr. Kassim wanted from her.

He sought to address the underlying triggers of her pain: sickle cell, worn joints, her menstrual cycle, nerve damage and prolonged opioid use. The main thing, he said, was to stabilize her quality of life. That goal motivated her.

But the spread of the coronavirus has interfered with their plan.

Dr. Kassim told Ms. Craig during a visit in February of last year that he wanted her to get an M.R.I. to better understand the underlying causes of her pain. But the pandemic hit, and she was not able to get that imaging until December. It revealed some of the pain triggers that Ms. Craig will have to get under control: a bulging disk in her back, and arthritis in both hips and her left shoulder.

She held off going to physical therapy for fear of catching Covid-19, but is now planning to go since she has been vaccinated. She has tried to tolerate the pain and avoid the hospital, but not always successfully. There were three visits in a week last June and a five-hour wait during a September visit.

Through the past year, she has grown more resolute, trying to raise awareness and support for people with the disease in Knoxville. She had masks made with the words “sickle cell” printed across the front. She has resolved to live with the disease, not suffer from it.

“It’s just my life,” she said. “The one I’ve been dealt.”

Categories
World News

Inventory futures edge greater following a rebound day on Wall Avenue

Traders on the floor of the New York Stock Exchange.

Source: NYSE

Stock futures rose early Friday after averages rebounded from a three-day losing streak the day before, led by technology stocks.

Futures on the Dow Jones Industrial Average showed an opening gain of around 65 points. S&P 500 futures and Nasdaq 100 futures also traded slightly higher.

The futures move followed a comeback day on Wall Street with the Dow gaining 186 points and the S&P 500 and Nasdaq Composite ending the day 1.06% and 1.77% higher, respectively. Microsoft, Facebook, and Alphabet all gained more than 1%, while Netflix and Apple each gained more than 2%.

Stocks of Tesla and other speculative parts of the market rebounded as Bitcoin prices rebounded after a roller coaster ride on Wednesday. However, Bitcoin briefly went negative after the finance department called for stricter cryptocurrency compliance with the IRS.

A new pandemic low in unemployment claims also added to the mood on Thursday. Initial unemployment benefits for the week ending May 15 stood at 444,000, the lowest since March 14, 2020, the Labor Department reported Thursday. Economists polled by Dow Jones had expected 452,000 new claims.

“Thursday’s improvement in jobless claims confirms our view that April’s disappointing job report was more of a slip than a sign of slowdown, and we expect the labor market to see significant improvement in the coming months,” he said Scott Ruesterholz, Portfolio Manager at Insight Investment.

Despite Thursday’s rebound, the Dow is down 0.9% over the past week on track to see its fourth negative week in the past five weeks. The S&P 500 is 0.4% lower from the week, in line with the pace of the second negative week in a row. The Nasdaq Composite is up 0.8% and is positioned to break a 4-week losing streak.

Home Depot shares rose 0.66% in expanded trading Thursday after the retailer announced a new $ 20 billion share buyback program. Home Depot’s announcement came after the company reported first quarter earnings and sales on Tuesday that weighed on analysts’ expectations

– CNBC’s Yun Li contributed to this report.

Categories
World News

Japan shares edge larger as main markets in Asia-Pacific are closed

SINGAPORE – Japanese stocks rose Monday afternoon as many major Asia Pacific markets are closed for public holidays.

In Japan, the Nikkei 225 was up 0.91% while the Topix index was up 0.66%.

South Korea’s Kospi hovered over the flatline. LG Electronics’ shares rose approximately 0.6%. The company announced on Monday that it was closing its mobile division to focus resources on “growth areas” like electric vehicle components.

The broadest MSCI index for stocks in the Asia-Pacific region outside of Japan has hardly changed.

The markets in Australia, Mainland China and Hong Kong are closed on Mondays for public holidays.

US payrolls exceed expectations

In terms of economic development, the U.S. Department of Labor reported Friday that the number of non-agricultural workers rose by 916,000 in March – well above the 675,000 increase that Dow Jones polled economists had expected.

The unemployment rate also fell to 6%, in line with the expectations of economists polled by Dow Jones.

Currencies and oil

The US dollar index, which tracks the greenback versus a basket of its peers, came in at 92.942 – up above 93.3 from late last month.

The Japanese yen was trading at 110.57 per dollar, weaker than 110.5 against the greenback last week. The Australian dollar changed hands at $ 0.7619, above the $ 0.756 level seen last week.

Oil prices were lower in the afternoon of Asian trading hours, with the international benchmark Brent crude oil futures falling 0.99% to $ 64.22 a barrel. US crude oil futures were down 0.91% to $ 60.89 a barrel.

Categories
Health

Monitoring the Climate on the Fringe of the World

It all started with a single sentence in a blog post about Iceland: “A farmer is looking for support in a weather station and a sheep farm.”

It was 2012 and after studying photography in the German industrial city of Dortmund, I was ready for a change. I had long planned to visit Iceland and when I read about the remote farm it all came together. I answered the mail, got the job, sold most of my stuff, and booked my flight.

Marsibil Erlendsdottir, the farmer and weather watcher, picked me up at the small airport in Egilsstadir near the easternmost edge of Iceland.

The drive to the weather station took almost two hours – through snow-covered mountain passes, along waterfalls, past reindeer and empty summer houses. As we neared our destination, the road became narrow and rough. Finally we reached the end of a remote fjord where a small yellow lighthouse appeared in the distance.

“Welcome to the end of the world,” said Mrs. Erlendsdottir with a laugh.

The Icelandic Meteorological Office operates 71 manned weather stations across the country, 57 of which report precipitation, snow depth and land cover once a day. Ms. Erlendsdottir, who passes Billa, supervises one of the 14 stations, which also report on cloud cover, weather conditions and other meteorological phenomena.

Regardless of the weather, Billa checks the readings from the weather instruments at her station every three hours, day and night, and forwards them – temperatures, air pressure, wind conditions and others – to the office in Reykjavik.

Their reports are published online and broadcast on the radio along with those from the rest of the country. For farmers who rely on the forecasts, the information provided by Billa can help guide their daily work. For fishermen on the high seas, the information can mean the difference between life and death.

There has been a weather station in this area since 1938, always operated by real people. (Given the harsh conditions in the region, automation wouldn’t be possible, says Billa.)

The region is incredibly remote. In the coldest months of the year, the farm can only be reached by boat and can be cut off from the outside world for days during storms.

Billa grew up on the weather station with her brother and five sisters. She married one of the local fishermen and had a family of her own that raised two children – one of whom, her son, was born on a boat on the way to the hospital.

Billa’s husband died in recent years, leaving her to run the weather station and the farm on her own. Billa could have easily left the place, but she decided to stay.

“It never gets boring here,” she said.

I worked with Billa for 10 months at the beginning. Growing up on a farm in Poland, I found much of the job familiar: looking after the sheep, training Border Collies, repairing fences, collecting hay.

Billa doesn’t enjoy the limelight. It took over a year before she felt comfortable enough for me to take her portrait.

In the meantime, I began to document her life and work to the rhythm of her days – and the weather reports.

Like Billa, I like to spend time off the grid and keep coming back to the farm where there is no cell phone reception. In total, I spent about two and a half years there.

The area becomes inaccessible, especially in the winter months when daylight lasts only a few hours and the constantly rotating beam from the lighthouse cuts through the darkness.

For months the farm is covered in snow and the sounds are muffled – with the exception of the sounds of the surrounding sea. In winter the waves get wilder and wilder, the wind stronger and stronger and the weather conditions less predictable.

But even in the toughest snowstorm, Billa leaves her house to look after the animals and check the protection of the instruments.

Each season has its own chores. In spring, when the sheep give birth, the animals must be monitored 24 hours a day. In summer the hay has to be collected for the winter months. And in autumn the sheep are carried down from the mountains.

In addition to all the work on the farm, Billa also maintains the lighthouse, which was built in 1908. Your pantry must always be full, as the nearest supermarket is 80 km away.

In winter it takes an hour by boat to get to the nearest shops. A mail boat arrives every two weeks, but only if weather conditions permit.

The circumstances here are immensely demanding, but living in harmony with nature gives Billa a feeling of inner peace. She cannot sit still and spends as much time outside as possible.

A few years ago, Billa’s daughter Adalheidur, who passed Heida, finished her studies in Reykjavik and moved back to the farm to accompany and help her mother.

“If I ever moved away, my mother would definitely stay here alone,” said Heida.

“Here,” she added, “she feels free.”

Categories
Health

For a Nation on Edge, Antacids Turn into Exhausting to Discover

At first it was toilet paper. Then it was meat.

Now it’s antacids.

People who search for over-the-counter belly pacifiers online or in stores are finding that parts of the country cannot simply buy antacids like tums, pepcid, and the generic version famotidine. A few weeks ago Wegmans Food Markets took the step of restricting buyers to two packets of famotidine products per trip.

During a hoarding pandemic, this can be the most unexpected.

Americans are stressed out. They are concerned about the rising number of coronavirus cases. They care about their work. Distance learning is a nightmare, and grocery shopping is no walk in the park. Not to mention the elections. And now the holidays are coming. The result is that some people are experiencing “pandemic stomach,” acid-generating episodes that increase the demand for over-the-counter and prescription antacids.

And antacids are also popular with people who are new to indigestion or heartburn. People started stocking up on them after preliminary studies suggested that famotidine could relieve symptoms of the coronavirus. Another wave of purchases hit this fall when President Trump was under treatment for coronavirus and White House officials said he was given famotidine along with zinc and vitamin D.

For those in need of relief, the bottlenecks are insane.

When 24-year-old Maia Callahan, a young early education graduate who teaches families and teaches distance learning in Greenfield, Massachusetts, attempted to put her usual order of Pepcid in her online Stop & Shop shopping cart in early September, it said again and again that the product is out of stock.

“I thought, OK, I’m going to place an order through Amazon,” said Ms. Callahan, who has an autoimmune disease and has been taking medication to treat her heartburn since she was 17. “That was the worst. One of the heartburn drugs was three times as expensive as usual. I took Tums for two weeks.”

Doctors said when the quarantines were lifted this spring, they noticed more patients reporting symptoms of heartburn and acid reflux.

“I think part of that is the stress of everything that’s going on in the world,” said Dr. Lauren Bleich, a gastroenterologist in Acton, Massachusetts, about 25 miles northwest of Boston, who said she saw a 25 percent increase in patients reporting heartburn and similar symptoms.

But she also said that the coronavirus, which has uprooted people’s normal lives and forced many to work from home, has led to many “dietary indiscretions” that trigger these symptoms.

“We are more relaxed than before with alcohol, sweets or our comfort food,” said Dr. Pale. “And then there is a lack of activity or movement. Weight gain definitely contributes to heartburn and acid reflux. “

Another perpetrator appeared in early November.

“We had many people with upset stomachs, heartburn and indigestion related to the elections,” she said.

Dr. Atul Maini, the medical director of the Heartburn Center at St. Joseph’s Health in Syracuse, NY, said that while the specialized center did not see an increase in patients, it did see a huge difference between the patients it has treated since the coronavirus quarantines have been lifted.

“The heartburn patients were now very anxious and depressed,” he said. “Something else had changed.”

Companies that make over-the-counter drugs are trying to meet demand.

“We are aware that there may be supply shortages,” said a spokeswoman for GlaxoSmithKline, which manufactures Tums, in an email.

However, for some antacids, the surge in demand may be linked to various preliminary studies suggesting that famotidine, the main ingredient in Pepcid, may reduce symptoms of the coronavirus.

In the spring, some patients with Covid-19 at Northwell Health in the New York City area received intravenous famotidine as part of a clinical trial following reports of use in China. The study was halted in May as patient volumes decreased and no conclusions were drawn. An observational study published earlier this fall by Hartford Hospital in Connecticut found positive results were also seen in coronavirus patients given famotidine.

Of the roughly 900 Hartford Hospital patients treated for coronavirus this spring, 83 were given famotidine at some point during their hospital stay. Those who received famotidine had lower hospital death rates and needed less help breathing a ventilator, the hospital said in its research report.

Still, the medical community is cautious about early results. In late June, the Infectious Diseases Society of America recommended the use of famotidine unless it was done in a clinical trial due to insufficient data.

Even before the preliminary research reports were published, demand for famotidine and Pepcid had risen sharply after the Food and Drug Administration asked companies to stop selling all forms of the heartburn drug Zantac in April and recommended consumers take it over the counter have version known as ranitidine, stop that. Small amounts of a carcinogenic chemical have been found in samples of the drug.

As consumers and doctors switched from Zantac to generic famotidine and pepcid, drug makers struggled to keep up. Some manufacturers reported drug shortages to the FDA earlier this year.

Johnson & Johnson, makers of Pepcid, did not respond to a request for comment. In July, company executives announced that US over-the-counter drug sales rose 30 percent in the second quarter, driven by strong demand for Tylenol, Pepcid, and other adult products.

For those who have taken Pepcid or generic versions of Famotidine, the past few months have been a struggle.

“I got a bottle in February but haven’t had one since,” said Mackenzie Doyle, a 21-year-old student at the University of Nebraska at Lincoln who is taking Pepcid with prescription strength to treat her immune disease. It will also be difficult to find over-the-counter Pepcid this spring, she said. When she visited her parents in Alabama during the spring break, Pepcid was sold out in the four stores she visited.

“When the first round of panic buying went on, it was impossible to find Pepcid,” said Ms. Doyle, who eventually found a generic famotidine at Walgreens and took double the dose to reach her prescription strength.

Ms. Doyle admits she has mixed feelings about the pre-studies on famotidine and coronavirus. While assisting the research, she wonders if the names of the drugs used could be withheld until more became known.

And then there are the just-in-case hoarders.

“They make me a little angry,” said Ms. Doyle. “There are so many people who have my immune disorder and who are worse than me and who need these drugs to stay alive. Having people buy it and keep it in their bathroom cabinet and never open the bottle makes me nervous. “